Group items tagged

The Association of the British Pharmaceutical Industry (ABPI) has laid out a series of urgent actions it wants the newly elected Labour government to implement within its first 100 days in office. Among the top priorities, the ABPI has emphasised the urgent need to appoint a new Chair and Chief Executive for the Medicines and Healthcare products Regulatory Agency (MHRA). Additionally, the ABPI has urged the new government to launch the Life Sciences Manufacturing Capital Grants Facility without delay. Other measures the ABPI wants Labour to prioritise include: Rapidly passing outstanding UK clinical trials legislation to enhance the UK's attractiveness for inward investment, including into research within the NHS. Increasing commercial flexibility in the NHS England Commercial Framework for New Medicines to remove barriers for companies to launch new medicines and indications so that NHS patients can access the latest innovative medicines.

As Health Secretary Wes Streeting initiates a national conversation about the future of the NHS, the Association of the British Pharmaceutical Industry (ABPI) has stressed the importance of increasing investment in medicines to fix the 'broken' NHS. Streeting is inviting the public, NHS staff, and experts to share their experiences and contribute to shaping the government's 10 Year Health Plan to build an NHS fit for the future. The government aims to implement three big shifts to transform the NHS: hospital to community, analogue to digital, and sickness to prevention. Richard Torbett, chief executive of the ABPI, has highlighted the vital role medicines and vaccines can play in achieving these priorities. He said: "Wes Streeting is spot-on in identifying three strategic shifts necessary to fix the broken NHS. Medicines and vaccines have a vital role in all three of these priorities, but we are not currently realising their potential."

"The UK remains genuinely world-leading for life sciences in numerous areas - yet we continue to underperform on our potential," said Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI). His statement is based on recent government data indicating that the UK is not fully capitalizing on its strong historical and institutional advantages in life sciences across a range of economic, health, and research indicators. The latest 'Life sciences competitiveness indicators 2024' report from the government's Office for Life Sciences revealed that while the pharmaceutical industry leads in R&D spending with £9 billion in 2022, representing a fifth of total business investment, the country saw a notable decline in foreign direct investment (FDI), industry clinical trials, and exports. In 2023, FDI dropped by 21 per cent to £0.8 billion, following a trend that saw a 52 per cent decrease over the previous two years, including a £0.9 billion fall in FDI the year prior.